Celgene's AML drug clears late-stage test
Celgene is gearing up for regulatory submissions after a pivotal acute myeloid leukemia (AML) study showed its drug helped patients live longer.
The drugmaker — which is in the process of being swallowed by Bristol-Myers Squibb $BMY — tested its experimental drug, CC-486, in newly-diagnosed patients with AML who fully or partially benefited from chemotherapy.
In the 472-patient QUAZAR AML-001 trial, patients on supportive care were either given CC-486 or a placebo once daily for two weeks. Maintenance treatment with CC-486 conferred a statistically significant improvement in overall survival — meeting the main goal — as well as the endpoint of relapse-free survival, Celgene $CELG said on Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.